drugset / Trial / NCT06366217

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

NCT06366217

Phase 4 Not yet recruiting 100 enrolled University of California, San Francisco
RandomizedParallel-groupOpen-labelHealth-services research

Summary

To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.

Timeline

Start
2024-09-30
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Phenylephrine Small molecule 2.5 % Topical
Subject tropicamide Small molecule 1 % Topical